Lupin Launches Authorized Generic Version of Apriso®

Pharma major Lupin Limited (Lupin) announced the launch of authorized generic version of Bausch Health's Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.

Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso® had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.839.9 as compared to the previous close of Rs. 857.1. The total number of shares traded during the day was 101636 in over 3469 trades.

The stock hit an intraday high of Rs. 869.9 and intraday low of 833.8. The net turnover during the day was Rs. 86690663.

Source : Equity Bulls

Keywords